Clinical Trial Update: DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating dapagliflozin on exercise capacity in heart failure with preserved ejection fraction; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 3 | Status: COMPLETED | Results posted: 2021-11-17